Impact BioMedical, Inc. (IBO)
5.62
-0.03
(-0.53%)
USD |
NYAM |
Sep 25, 15:32
Impact BioMedical Cash from Operations (TTM) : -0.508M for June 30, 2026
Cash from Operations (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Operations (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | -0.508M |
| March 31, 2026 | -1.672M |
| December 31, 2025 | -1.89M |
| September 30, 2025 | -3.245M |
| June 30, 2025 | -3.917M |
| March 31, 2025 | -4.119M |
| December 31, 2024 | -3.919M |
| September 30, 2024 | -3.096M |
| June 30, 2024 | -2.482M |
| Date | Value |
|---|---|
| March 31, 2024 | -2.319M |
| December 31, 2023 | -2.851M |
| September 30, 2023 | -2.781M |
| June 30, 2023 | -2.912M |
| March 31, 2023 | -2.723M |
| December 31, 2022 | -2.242M |
| September 30, 2022 | -2.669M |
| June 30, 2022 | -2.360M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (TTM) Benchmarks
| LENZ Therapeutics, Inc. | -113.91M |
| Enveric Biosciences, Inc. | -8.561M |
| ANI Pharmaceuticals, Inc. | 189.47M |
| Corcept Therapeutics, Inc. | 109.70M |
| Veru, Inc. | -26.04M |